Aspire Biopharma Holdings (ASBP) Accounts Payables (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Accounts Payables came in at $857925.0 in Q1 2026, down 40.09% year-on-year from $1.4 million in Q1 2025, and down 15.42% on a QoQ basis from $1.0 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Accounts Payables (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 6 years of Accounts Payables data on file, last reported at $857925.0 in Q1 2026.
- On a quarterly basis, Accounts Payables fell 40.09% year-over-year to $857925.0 in Q1 2026; TTM through Mar 2026 was $857925.0, a 40.09% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, up 226.99% from the prior year.
- Accounts Payables for Q1 2026 stood at $857925.0, down from $1.0 million in the prior quarter.
- Over the last five years, Accounts Payables for ASBP reached as high as $1.4 million in Q1 2025 and fell as low as $19067.0 in Q1 2022.
- Historically, Accounts Payables has averaged $494839.9 across 5 years, with a median of $256975.5 in 2023.
- Across the five-year window, Accounts Payables jumped 66066.3% in 2022 and tumbled 40.09% in 2026, its largest moves.
- Year by year, Accounts Payables stood at $180634.0 in 2022, then decreased by 15.85% to $152005.0 in 2023, then jumped by 104.08% to $310219.0 in 2024, then surged by 226.99% to $1.0 million in 2025, then slipped by 15.42% to $857925.0 in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $857925.0 in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Aspire Biopharma Holdings | 1.21 Mn | -619,284.29 | 5,750.00 | 857,925.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 857,925.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | 310,219.00 |
| Jun 30, 2024 | 584,078.00 |
| Mar 31, 2024 | 365,010.00 |
| Dec 31, 2023 | 152,005.00 |
| Sep 30, 2023 | 104,379.00 |
| Jun 30, 2023 | 101,667.00 |
| Mar 31, 2023 | 203,732.00 |
| Dec 31, 2022 | 180,634.00 |
| Sep 30, 2022 | 96,016.00 |
| Jun 30, 2022 | 83,777.00 |
| Mar 31, 2022 | 19,067.00 |
| Dec 31, 2021 | 273.00 |